Message from the Editors to our Reviewers

TY - JOUR

T1 - Message from the Editors to our Reviewers

AU - Gross, Robert A.

AU - Worrall, Bradford B.

AU - Amato, Anthony A.

AU - Cascino, Gregory D.

AU - Ciccarelli, Olga

AU - Corboy, John R.

AU - Dalmau, Josep O.

AU - Gottesman, Rebecca F.

AU - Grossman, Murray

AU - Millichap, John J.

AU - Mink, Jonathan W.

AU - Pulst, Stefan M.

AU - Uitti, Ryan J.

N1 - Funding Information: Jonathan W. Mink, MD, PhD, FAAN, receives research support from NIH/NINDS, the Batten Research Alliance, and Abeona, Inc. He is a consultant for Abide Therapeutics, Censa, Inc, the Beyond Batten Disease Foundation, and TEVA. He is Associate Editor of Neurology. He is an Editorial Board member for Journal of Clinical Movement Disorders, Pediatric Neurology, and the Journal of Child Neurology. Funding Information: John R. Corboy, MD, FAAN, conducts research supported by Novartis, the National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, and Med Day. He is a consultant to Novartis and Mylan. Dr. Corboy has received honoraria for speaking from Prime CME and the Rocky Mountain MS Center. He is an Associate Editor of Neurology and Editor of Neurology® Clinical Practice. Funding Information: Murray Grossman, MDCM, is supported by the NIH as principal investigator, core leader, or project leader; the Wyncote Foundation; the Arking Family Foundation; and the Samuel Newhouse Foundation. He is Chair of the Behavioral Neurology Section, AAN; and Chair, Society for Behavioral and Cognitive Neurology. He is on the Medical Advisory Board of the Association for Frontotemporal Degenerations and on the Executive Board of the International Society for Frontotemporal Dementia. Dr. Grossman is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. He received compensation for consultation from Bracco, UCB, Biogen, and Ionis. His laboratory receives research funding for imaging studies sponsored by Life, Biogen, and Avid. He participates in clinical trials sponsored by Biogen, Alector, and Eisai. He receives an honorarium as Associate Editor of Neurology. Funding Information: Josep O. Dalmau, MD, PhD, conducts research supported by Instituto Carlos III (FIS 17/00234, PIE 16/00014, and AC18/00009)–Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya), La Caixa Foundation (HR17-00149), the CELLEX Foundation, Sage Therapeutics, and the Edmond J Safra Foundation. He consults for Advance Medica and holds the following patents: Ma2 autoantibody test, US patent number 6,387,639; NMDA receptor autoantibody test, US patent number 7,972,796 B2, European patent number 2057466; GABA(B) receptor autoantibody test, US patent number 8,685,656, European patent number 2483417; DPPX autoantibody test, US patent number 9,719,993. Patents are filed for GABA(A) receptor autoantibody and IgLON5 autoantibody test. In 2016, Dr. Dalmau received a one-time licensing fee for the Iglon5 autoantibody test/Euroimmun. He is on the editorial boards of Neurology and UptoDate and receives a stipend as the Editor of Neurology® Neuroimmunology & Neuroinflammation. Dr. Dalmau receives royalties from Athena Diagnostics (Ma2 patent) and Euroimmun (NMDA, GABA[B], DPPX, and GABA[A] patents). Funding Information: Olga Ciccarelli, MD, PhD, FRCP, is a National Institute for Health Research (NIHR) Research Professor. She receives research support from the UK MS Society, National MS Society, Rosetrees Trust, ECTRIMS/MAGNIMS, EU Horizon 2020, and NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC). She serves as a consultant for Merck, Biogen, Novartis, Teva, Genzyme, and Roche. She is on the Editorial Board of Multiple Sclerosis Journal and receives an honorarium from the AAN as Associate Editor of Neurology. Funding Information: John J. Millichap, MD, FAAN, FAAP, receives research support from NIH, Citizens United for Research in Epilepsy (CURE), and Pediatric Epilepsy Research Foundation (PERF). He volunteers on the medical advisory board of The Jack Pribaz Foundation (KCNQ2.org) and as the Editor of Pediatric Neurology Briefs. He receives royalties for online monographs from Up-To-Date. He served as a consultant for Eisai, Sunovion, Nutricia, Xenon, Ionis, and BioMarin. He receives an honorarium as Associate Editor of Neurology. Funding Information: Robert A. Gross, MD, PhD, FAAN, is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Since his appointment as Editor-in-Chief in 2009, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from the AAN as Editor-in-Chief of Neurology. Funding Information: Bradford B. Worrall, MD, MSc, FAAN (FANA and FAHA), has received research funding from NIH (multiple grants). He serves as site PI for a phase II clinical trial of CN-105 (sponsor AegisCN, LLC, IND#119278). Dr. Worrall serves as site PI for a phase II clinical trial of CN-105 (sponsor AegisCN, LLC, IND#119278) and serves as an ad hoc reviewer for the NIH, Veterans Administration, and UK-MRC study sections. Dr. Worrall received several honoraria for serving as faculty and/or director for courses at AAN annual meetings. Dr. Worrall receives an honorarium as Deputy Editor of Neurology. Funding Information: Gregory D. Cascino, MD, FAAN has received honoraria for serving as faculty for education courses at the annual meeting of the AAN. He has received royalties from the Mayo Foundation–Mayo Medical Ventures (high-frequency nerve stimulation to treat lower back pain, Nevro). He has had research support from the Epilepsy Study Consortium, UCB, Inc., GW Pharmaceuticals, Neurelis, Inc., Medtronic Navigation, Inc., Neuropace, and the Mayo Foundation. He receives an honorarium from the AAN as Associate Editor of Funding Information: Ryan J. Uitti, MD, FAAN, has received research funding from the NIH, AbbVie, and Boston Scientific. His institution has received annual royalties from the licensing of the technology related to PARK8/LRRK2 greater than the federal threshold for significant financial interest; Dr. Uitti has not received any royalties. Dr. Uitti receives an honorarium as Associate Editor of Neurology.

PY - 2019/7/2

Y1 - 2019/7/2

UR - http://www.scopus.com/inward/record.url?scp=85073695498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073695498&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007723

DO - 10.1212/WNL.0000000000007723

M3 - Editorial

AN - SCOPUS:85073695498

SN - 0028-3878

VL - 93

SP - 3

EP - 12

JO - Neurology

JF - Neurology

IS - 1

ER -